Targeted therapy

Authors: Sarah Gierahn Nielsen, med. student & Hanne Melgaard Nielsen, MD Since 2006 , where trastuzumab (a monoclonal antibody) has been offered as adjuvant treatment to HER-2 positive patients, the risk of recurrence have been significantly reduced. It may be given as a subcutaneous injection ever